View Schedule

9 a.m.–3:15 p.m. EST*

Immunotherapy Resistance and Failure 

Edward Cha, MD, PhD - Genentech

Session I: Defining Immune Checkpoint Inhibitor Resistance

9:05 a.m.

Definitions of Resistance and Gaps in Current Understanding
Ryan J. Sullivan, MD - Massachusetts General Hospital

9:35 a.m.

9:55 a.m.

Immunotherapy Primary and Acquired Resistance (View On-Demand)
Antoni Ribas, MD, PhD - University of California Los Angeles

10:15 a.m.

Break

Session II: Primary Resistance

Approaches to Address Primary Resistance
Siwen Hu-Lieskovan, MD, PhD – Huntsman Cancer Institute, University of Utah

Neoadjuvant Immune Checkpoint Blockade: A Window into Treatment Response and Primary Resistance (View On-Demand)
Suzanne L. Topalian, MD - Johns Hopkins University School of Medicine

Coupled scRNA-seq and Intracellular Protein Activity Reveals Immune Suppressive Role of TREM2 in Cancer (View On-Demand)
Yonatan Katzenelenbogen, B.Sc - Weizmann Institute of Science

¬MHC-I and -II Expression Levels on Tumor cells and T cell Response to Immunotherapy in B78 Murine Melanoma Model
Amy K. Erbe, PhD - University of Wisconsin

Break

Approaches to Address Acquired Resistance
Kevin J. Harrington, PhD, MD - The Institute of Cancer Research

12:45 p.m.

Overcoming Acquired Resistance in anti-PD-1 Therapy by Simultaneously Depleting Tumor and All Major Types of Immunosuppressive cells
Yong Lu, PhD - Wake Forest School of Medicine

Preclinical Antitumor Activity of OncoVEXmGM-CSF in Combination with PD-1/PD-L1 Inhibitors in PD-L1 Resistant Mouse Models Supports the MASTERKEY-115 Study
Jing Qing, PhD - Amgen Inc.

Break

Assessment of Circulating Tumor DNA (ctDNA) and Plasma Microsatellite Instability (MSI) during PD-1 Blockade
Pashtoon M. Kasi, MD, MS - University of Iowa

Radiological Dynamics and Resistance Types in Patients with Advanced Melanoma Treated with anti-PD-1 Monotherapy (View On-Demand)
Xue Bai, MD - Peking University Cancer Hospital & MGH

Precision Microbiome Mapping Identifies a Microbiome Signature Predictive of Immune Checkpoint Inhibitor Response Across Multiple Research Study Cohorts
Matthew J. Robinson, PhD - Microbiotica

Regulatory Considerations
Marc Theoret, MD - U.S. Food and Drug Administration, OHOP

Panel Discussion

Closing Remarks
Israel Lowy, MD, PhD - Regeneron Pharmaceuticals

7:30–8:30 a.m. EST

8 a.m.–9 a.m. EST

World Immunotherapy Council's Virtual Young Investigator Session

Introduction
Bernard A. Fox, PhD - Providence Cancer Institute

8:05 a.m.

A combination of functional biomarkers improves identification of the tumor-specific reactive T cell repertoire (View On-Demand)
Arianna Draghi – National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital

8:15 a.m.

Deep immune profiling of SARS-CoV-2 associated immune microenvironment in cancer tissues from recovered COVID-19 patients
Denise Goh, BBiomedSc (Hons) – Institute of Molecular and Cell Biology (IMCB), Agency of Science, Technology and Research (A*STAR), Singapore

8:25 a.m.

Expert Discussant
Tanja D. de Gruijl, PhD – VU University Amsterdam

Anti-LunX targeting therapy for lung cancer
Xiaohu Zheng – University of Science and Technology of China

8:40 a.m.

Identification of tumor antigen-specific T cells in the peripheral blood of colorectal cancer patients
Emilie Picard, PhD – Health Sciences North/Horizon Sante Nord

Expert Discussant 
Bernard A. Fox, PhD – Providence Cancer Institute

Closing  
Bernard A. Fox, PhD – Providence Cancer Institute

9 a.m.–11:45 a.m. EST

Grant Writing Workshop

Welcome Remarks
Claire Vanpouille-Box, PhD – Weill Medical College of Cornell University

9:05 a.m.

Overview of Grant Opportunities and Principles of Grant Writing (View On-Demand)
Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute

9:30 a.m.

K Awards and R01 Grants (View On-Demand)
William Matsui, MD – University of Texas at Austin

9:55 a.m.

How to Write a Specific Aims Page  (View On-Demand)
Thomas Gajewski, MD, PhD – University of Chicago

Panel Discussion 
Moderator:
David Aggen, MD, PhD – Memorial Sloan Kettering Cancer Center

Panelists:
William Matsui, MD – University of Texas at Austin
Thomas Gajewski, MD, PhD – University of Chicago
Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute
Malgorzata Klauzinska, PhD – National Institutes of Health

Mock Study Section
Moderator:
Zhang-Zhi Hu, MD- National Institute of Health

Panelists:
Scientific Review Officer - Malgorzata Klauzinska, PhD – National Institutes of Health
Chair - Thomas Gajewski, PhD – University of Chicago
Primary Reviewer - Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute
Secondary Reviewer - William Matsui, MD – University of Texas at Austin
Third Reviewer – Robyn Gartrell, MD – Columbia University/New York Presbyterian
Reader - Olivia Rongze Lu, PhD – University of Texas at Austin, Dell Medical School

What Happens After the Study Section? (View On-Demand)
Malgorzata Klauzinska, PhD – National Institutes of Health

Panel Discussion 
Moderator:
Grey Wilkinson, PhD – Oncolytics Biotech Inc.

Panelists:
William Matsui, MD – University of Texas at Austin
Thomas Gajewski, PhD – University of Chicago
Pawel Kalinski, PhD – Roswell Park Comprehensive Cancer Institute
Malgorzata Klauzinska, PhD – National Institutes of Health
Zhang-Zhi Hu, MD- National Institute of Health

Closing Remarks
Olivia Rongze Lu, PhD – University of Texas at Austin, Dell Medical School

9 a.m.–2:55 p.m. EST 

Workshop on Engineering Immune Cells for Cancer Therapy 

Session I: Advances in Adoptive T cell Therapy for Cancer: TILs and TCRs

Katy Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center

9:05 a.m.

Cellular Immunotherapy for Metastatic Cancers (View On-Demand)
Steven A. Rosenberg, MD, PhD – National Cancer Institute, National Institutes of Health

9:25 a.m.

Adoptive Therapy Utilizing TILs (View On-Demand)
John Haanen, MD, PhD – Netherlands Cancer Institute

9:45 a.m.

Endogenous T cell Therapy for Solid Tumors Malignancies (View On-Demand)
Cassian Yee, MD – The University of Texas MD Anderson Cancer Center

10:05 a.m.

Session I Panel Discussion - Session I Speakers

10:20 a.m.

Break

Session II: Novel Approaches to Enhance CAR T cell Therapy

Next-generation CARs for Blood Cancers
Michael Hudecek, MD –University of Wuerzburg

Advancing Immunotherapy Platforms for the Treatment of Solid Tumors
Saul Priceman, PhD – City of Hope

Understanding Resistance to CAR T-cell Therapy to Develop Next-generation Immunotherapies
Marco Ruella, MD – University of Pennsylvania

Session II Panel Discussion - Session II Speakers

Break

CAR NK cells for the Immunotherapy of Cancer 
Katy Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center

12:25 p.m.

The Development of CAR Macrophages and Monocytes for Cancer Immunotherapy
Michael Klichinsky, PharmD, PhD – Carisma Therapeutics

Engineering B cells to Produce Therapeutic Antibodies
Justin J. Taylor, PhD – Fred Hutchinson Cancer Research Center

Session III Panel Discussion - Session III Speakers

Break

The Evolving Process of Clinical CAR T Cell Manufacturing in the Academic Setting
Isabelle C. Rivière, PhD – Memorial Sloan Kettering Cancer Center

Allogeneic CAR T therapy for Cancer
Barbra J. Sasu, PhD – Allogene Therapeutics

Corona Madness: Flattening the Curve with CAR T (View On-Demand)
Carl H. June, MD – University of Pennsylvania

Session IV Panel Discussion - Session IV Speakers

Closing Remarks
Christine Brown, PhD – City of Hope

9 a.m.–3:55 p.m. EST

Primer on Tumor Immunology and Cancer Immunotherapy™

(CE Credit Available)

Session I: Generating Anti-Tumor Immunity

Introduction
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center

9:05 a.m.

The Adaptive Immune Response
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine

9:35 a.m.

Dendritic Cells and Myeloid cues in the Tumor Microenvironment
Niroshana Anandasabapathy, MD, PhD - Weill Cornell Medicine

10 a.m.

Myeloid-derived Suppressor Cells as Negative Regulators of Immune Responses in Cancer (View On-Demand)
Dmitry I. Gabrilovich, MD, PhD – AstraZeneca

Session I Panel Discussion - Session I Speakers

10:40 a.m.

Break

Session II: Approaches to Immunotherapy I

Introduction
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center

T cell Checkpoint Blockade/Costimulation (View On-Demand)
James P. Allison, PhD – The University of Texas MD Anderson Cancer Center

Cancer Vaccines 
Ugur Sahin, MD – BioNTech Group 
(*No Credit) 

The Suppressive Yin Versus Pro-Inflammatory Yang of the Tumor Myeloid Stroma (View On-Demand)
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center

Session II Panel Discussion - Session II Speakers

Break

Introduction
Yvonne Saenger, MD – Columbia University/New York Presbyterian

12:55 p.m.

Be all that you can B: Imprinting an Antitumor T cell Army
Chrystal M. Paulos, PhD – Winship Cancer Institute at Emory University 

Immunometabolism and its Potential to Modify the Tumor Microenvironment (View On-Demand)
Greg M. Delgoffe, PhD – University of Pittsburgh

Mobilizing the Immune System with Bispecific Antibodies (View On-Demand)
John R. Desjarlais, PhD – Xencor, Inc.

Session III Panel Discussion - Session III Speakers

Break

Introduction
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center

Immune Biomarkers to Guide Clinical Care (View On-Demand)
Yvonne Saenger, MD – Columbia University/New York Presbyterian

Immune Related Adverse Events (View On-Demand)
Michael Postow, MD – Memorial Sloan Kettering Cancer Center 

Session IV Panel Discussion - Session IV Speakers

Closing Remarks
Yvonne Saenger, MD – Columbia University/New York Presbyterian

7:30–8:30 a.m. EST

8–8:30 a.m. EST

Anniversary Awards Ceremony 
Chair:
Mario Sznol, MD – Yale School of Medicine
8:30–9 a.m. EST

8:30 a.m.

Introduction 
Mario Sznol, MD – Yale School of Medicine

Patient Advocacy Award

Session 100: Presidential Welcome & Rosenberg Award Announcement
Chair:
Mario Sznol, MD – Yale School of Medicine

9–9:30 a.m. EST

Mario Sznol, MD – Yale School of Medicine

Session 101: Richard V. Smalley, MD Memorial Award and Lectureship: Discovery, Development, and Application of the PD-1/PD-L1; B7-H1 Antagonist Antibodies
Chair:
Mario Sznol, MD – Yale School of Medicine
9:30–11 a.m. EST
(CE Credit Available)

9:30 a.m.

The PD-L1/PD-1 Pathway: Discovery and New Insights (View On-Demand)
Gordon Freeman, PhD – Dana-Farber Cancer Institute

10 a.m.

Why Were We Interested in Immunity Within the Tumor Microenvironment in the 1990s?
Lieping Chen, MD, PhD – Yale School of Medicine

10:30 a.m.

Discovery of New IO Targets and Mechanisms Leveraging CRISPR 
Arlene Sharpe, MD, PhD – Harvard Medical School
(*No Credit)

11–11:15 a.m. EST

Break

Session 102: Combinatorial Therapies
Co-Chairs:
Charlotte E. Ariyan, MD, PhD – Memorial Sloan Kettering Cancer Center
Silvia Formenti, MD – Weill Cornell Medicine
11:15 a.m.–1:10 p.m. EST
(CE Credit Available)
Organized in collaboration with the Radiosurgery Society (RSS)

11:15 a.m.

Introduction

11:20 a.m.

(470) Targeting Pan-Tumor Associated Antigen B7H3 via Combination of Tri-specific Killer Engager and Off-the-shelf NK Cell Therapy Enhances Specificity and Function Against a Broad Range of Solid Tumors
Nicholas Zorko, MD, PhD – University of Minnesota

(446) Immunopeptidome changes mediated by a novel ERAP1 inhibitor leads to tumor growth inhibition
Peter Joyce, PhD - Grey Wolf Therapeutics Limited

(362) A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis (View On-Demand)
James Spicer, PhD, FRCP - King's College London

Expert Discussant

Q&A

(200) NBTXR3 nanoparticle with immunoradiation improves survival and generates long-term anti-tumor memory in an anti-PD1 resistant Murine Lung Cancer Model (View On-Demand)
Yun Hu, PhD - The University of Texas MD Anderson Cancer Center

(368) REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors
Adi Diab, MD - The University of Texas MD Anderson Cancer Center

Expert Discussant
Chandan Guha, MB, BS, PhD – Montefiore Medical Center

Q&A

1:10–1:30 p.m. EST

Break

1–2 p.m. EST

Virtual Exhibit and Poster Hall Hours

Concurrent Session 103: Rapid Oral Abstract Presentation: Basic Research
Co-Chairs:
Sarah Church, PhD – NanoString Technologies
Brendan Horton, PhD – Massachusetts institute of Technology
1:30–2 p.m. EST

1:30 p.m.

(90) Potentiation of T-cell mediated tumor killing via modulation of the fas/fasL pathway (View On-Demand)
Jonathan Boiarsky, BA - Icahn School of Medicine at Mount Sinai

1:38 p.m.

(209) Preclinical mechanistic and clinical evaluation of the corticosteroid dexamethasone’s detrimental effects on immune checkpoint blockade in glioblastoma cancer (View On-Demand)
Bryan Iorgulescu, MD - Dana-Farber Cancer Institute

1:46 p.m.

(472) ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma (View On-Demand)
Natasha D. Sheybani, PhD - University of Virginia

1:54 p.m.

Q&A

Concurrent Session 104: Rapid Oral Abstract Presentation: Clinical
Co-Chairs:
Ravi Patel, MD, PhD – University of Pittsburgh
Jessica Thaxton, PhD, MSCR – Medical University of South Carolina
1:30–2 p.m. EST
(CE Credit Available)

1:30 p.m.

(420) Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study
Adi Diab, MD - The University of Texas MD Anderson Cancer Center

1:38 p.m.

(547) Identification of the immune landscape in penile squamous cell carcinoma using multiplex immunofluorescence and spatial image analysis
Rossana N. Lazcano Segura, MD - The University of Texas MD Anderson Cancer Center

1:46 p.m.

(455) Impact of EphB4 and PD-1 treatment on immune infiltrate in advanced bladder cancer (View On-Demand)
Sarmad Sadeghi, MD - Keck School of Medicine of USC

1:54 p.m.

Q&A

Session 105: Integrating Radiation and Immunotherapy: New Products, Challenges, and Opportunities for Industry-Academic Collaborations
Co-Chairs:
Zachary Morris, MD, PhD – University of Wisconsin, Madison
Andrew Sikora, MD, PhD – University of Texas MD Anderson Cancer Center
2–3:30 p.m. EST
(CE Credit Available)

2 p.m.

Introduction
Andrew Sikora, MD, PhD – University of Texas MD Anderson Cancer Center

2:05 p.m.

The Immuno-Radiobiology of Radiation Therapy (View On-Demand)
Zachary Morris, MD, PhD – University of Wisconsin, Madison

2:20 p.m.

Optimal Sequencing of Radiation and Immunotherapy
Silvia Formenti, MD – Weill Cornell Medicine

2:35 p.m.

Design of Clinical Trials Integrating Radiation and Immunotherapy (View On-Demand)
Jonathan D. Schoenfeld, MD, MPhil, MPH – Harvard University

2:50 p.m.

NCI SBIR Opportunities
Kory Hallet, PhD – NCI SBIR Development Center

3 p.m.

Best Practices and Future Perspectives for Integrating Radiation and Immunotherapy Panel Discussion
(*No Credit)
Mansoor Ahmed, PhD – National Cancer Institute
Michael Basseti, MD, PhD – University of Wisconsin, Madison
Sue L. Currie, PhD – Nektar Therapeutics
Sandra Demaria, MD – Weill Cornell Medicine
Silvia Formenti, MD – Weill Cornell Medicine
Kory Hallet, PhD – NCI SBIR Development Center
Tibor Keler, PhD – Celldex Therapeutics, Inc.
Samir Khleif, MD – Georgetown University Medical Center
Sophia Pfister, PhD – Varian
Jonathan D. Schoenfeld, MD, MPhil, MPH – Harvard University
Andrew Sharabi, MD, PhD – Moores Cancer Center
Chiayeng Wang, PhD – National Cancer Institute, NIH
Kristina H. Young, MD, PhD –Earle A. Chiles Research Institute

3:25 p.m.

Closing Remarks

3:30–4:45 p.m. EST

Break

Concurrent Session 106: Developing Cellular Therapies for Solid Cancers
Co-Chairs:
Stephanie L. Goff, MD, FACS – National Cancer Institute
Avery Posey, PhD – University of Pennsylvania School of Medicine
3:45–5:15 p.m. EST
(CE Credit Available)

3:45 p.m.

TILS (View On-Demand)
Michal Besser, PhD – The Sheba Medical Center at Tel Hashomer

4:05 p.m.

TCR Cells
James C. Yang, MD – National Cancer Institute

4:25 p.m.

CAR for Solid Tumors
Avery Posey, PhD – University of Pennsylvania School of Medicine

4:45 p.m.

NKT Cells
Andras A. Heczey, MD – Baylor College of Medicine

5:05 p.m.

(122) Guanylyl cyclase C as a target for CAR-T cell therapy in a metastatic gastric cancer model (View On-Demand)
Amanda N. Lisby, MS - Thomas Jefferson University

Concurrent Session 107: Neoadjuvant Immunotherapies
Co-Chairs:
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center
Janis M. Taube, MD, MSc – Johns Hopkins School of Medicine
3:45–5:15 p.m. EST
(CE Credit Available)

3:45 p.m.

Pan-Tumor Pathologic Response Assessment
Janis M. Taube, MD, MSc – Johns Hopkins School of Medicine

4:05 p.m.

Neoadjuvant Breast Cancer (View On-Demand)
Elizabeth A. Mittendorf, MD, PhD – Dana-Farber Cancer Institute Brigham & Woman's Cancer Institute

4:25 p.m.

Bladder Cancer (Treme/Durva) (View On-Demand)
Jianjun Gao, MD, PhD – The University of Texas MD Anderson Cancer Center

4:45 p.m.

(432) 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma
Reinhard Dummer, MD - University Hospital of Zurich

5 p.m.

(264) Correlation of virus-specific CD8+ T cells to clinical response following treatment with Pexa-Vec and Cemiplimab in patients with advanced renal cell carcinoma
Raquel Deering, PhD – Regeneron Pharmaceuticals, Inc.

Concurrent Session 108: Diet and Microbiome
Co-Chairs:
Jeremiah Faith, PhD – Icahn Institute for Data Science and Genomic Technology at Mt. Sinai
Laurence Zitvogel, MD, PhD – Institut Gustave Roussy
3:45–5:15 p.m. EST
(CE Credit Available)

3:45 p.m.

Introduction into Microbiome & Diet
Jeremiah Faith, PhD – Icahn Institute for Data Science and Genomic Technology at Mt. Sinai

4 p.m.

Micronutrients with Immunostimulatory Properties
Guido Kroemer, MD, PhD – Institut Gustave Roussy

4:20 p.m.

Linking the gut microbiome to cancer immunotherapy response
Meriem Messaoudene, PhD – CRCHUM, Bertrand Routy Lab

4:40 p.m.

Diet, the microbiome, and immune response: From observation to intervention
Jennifer L. McQuade, MD – The University of Texas MD Anderson Cancer Center

5 p.m.

(672) Identification of microbial-derived HLA-bound peptides in melanoma
Adi Nagler, MSc - Weizmann

Concurrent Session 109: Innate Immunity: The Next Generation of Targets for Anti-Cancer Immunotherapy
Co-Chairs:
Jennifer L. Guerriero, PhD – Dana-Farber Cancer Institute
Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center
3:45–5:15 p.m. EST
(CE Credit Available)

3:45 p.m.

Harnessing Tumor Associated Macrophages for Anti-Cancer Therapy (View On-Demand)
Jennifer L. Guerriero, PhD – Dana-Farber Cancer Institute

4:05 p.m.

Gamma-delta T cells
Adrian Hayday, FRS, F MedSci – Gamma Delta Therapeutics

4:25 p.m.

NK Cells
Andreas Lundqvist, PhD – Karolinska Institutet

4:45 p.m.

(531) AFM13-targeted blood and cord-blood-derived memory-like NK cells as therapy for CD30+ malignancies
Nancy D. Marin, PhD - Washington University, St. Louis

5 p.m.

(539) High dimensional analysis of the human lymph node during melanoma progression reveals shifts in myeloid content that relate to differential T cell content
Anastasia Prokopi, PhD - Amsterdam, UMC

5–6 p.m. EST

Virtual Exhibit and Poster Hall Hours

Session 110: E-Poster Viewing Session

5:15–5:45 p.m. EST

Howard L. Kaufman, MD, FACS – Immuneering Corporation
5:30–6:30 p.m. EST

5:30 p.m

5:35 p.m.

Oncolytic Viruses: The Importance of Surgical Input (View On-Demand)
Howard L. Kaufman, MD, FACS – Immuneering Corporation

6:30–7 p.m. EST

Break

Replay Session with Live Q&A: Session 103: Rapid Oral Abstracts: Basic Research

7–8 p.m. EST

Co-Chairs:
Sarah Church, PhD – NanoString Technologies
Brendan Horton, PhD – Massachusetts Institute of Technology

Replay Session with Live Q&A: Session 104: Rapid Oral Abstracts: Clinical

Co-Chairs:
Ravi Patel, MD, PhD – University of Pittsburgh
Jessica Thaxton, PhD, MSCR – Medical University of South Carolina

On-Demand Sessions

Update Session: National Cancer Institute (NCI) (View On-Demand)
Norman E. Sharpless, MD - National Cancer Institute

Update Session: Food and Drug Administration (FDA)
Raj Puri, MD, PhD – U.S. Food and Drug Administration

Update Session: FDA Oncology Center of Excellence (FDA OCE)
Marc Theoret, MD – U.S. Food and Drug Administration

Update Session: Cancer Immunotherapy Trials Network (CITN) (View On-Demand)
Martin A. Cheever, MD - Fred Hutchinson Cancer Research Center

Update Session: SITC Policy Committee
George J. Weiner, MD - University of Iowa, Holden Comprehensive Cancer Center

Update Session: SITC Women in Cancer Immunotherapy Network (WIN) (View On-Demand)
Lisa H. Butterfield, PhD – Parker Institute for Cancer Immunotherapy

Update Session: International Neoadjuvant Melanoma Consortium (INMC)
Elizabeth M. Burton, MBA – MD Anderson Cancer Center

7:30–8:30 a.m. EST

Anniversary Awards Ceremony
Chair: Mario Sznol, MD – Yale School of Medicine
8:30–9 a.m. EST

8:30 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

8:32 a.m.

Extraordinary Service Awards

8:44 a.m.

Visionary/Leagacy Award

Session 200: Keynote Address
Chair:
Mario Sznol, MD – Yale School of Medicine
9–9:50 a.m. EST
(CE Credit Available)

9 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

9:05 a.m.

Turning Immunologically Quiescent Tumors into Immune Responsive Cancers (View On-Demand)
Elizabeth M. Jaffee, MD – Sidney Kimmel Cancer Center, Johns Hopkins University

9:45 a.m.

Q&A
Elizabeth M. Jaffee, MD – Sidney Kimmel Cancer Center, Johns Hopkins University

9:50–10:05 a.m. EST

Break

Session 201: Exploring the Tumor Microenvironment
Co-Chairs:
Vincenzo Bronte, MD – University of Verona
Miriam Merad, MD, PhD– Icahn School of Medicine at Mount Sinai
10:05 a.m.–noon EST
(CE Credit Available)

10:05 a.m.

Introduction

10:15 a.m.

Stromal Cells in Health, Disease and Immunotherapy
Shannon J. Turley, PhD – Genentech

10:40 a.m.

Exploring and Exploiting the Immune Landscape in Brain Cancers (View On-Demand)
Johanna A. Joyce, PhD – University of Lausanne & Ludwig Institute for Cancer Research

11:05 a.m.

Investigating Genetic Control of the Tumor Microenvironment by Spatial Functional Genomics (View On-Demand)
Brian D. Brown, PhD – Icahn School of Medicine at Mount Sinai

11:30 a.m.

(670) TJ210 (MOR210), A Differentiated Anti-C5aR Antibody for Anti-Cancer Therapy
Jane Meng, PhD - I-Mab Biopharma

11:45 a.m.

(591) Comparison of Two oHSV Vectors for the Treatment of Glioblastoma (View On-Demand)
Joseph Jackson, PhD - University of Pittsburgh

Session 202: Late-Breaking Abstract Session
Noon–12:30 p.m. EST
Chair:
Sandra Demaria, MD – Weill Cornell Medicine
(CE Credit Available)

Noon (CE Credit Available)

(773) Phenotypic Correlates of Adoptive Cell Therapy Response in Melanoma (View On-Demand)
Sri Krishna, PhD – National Cancer Institute

12:15 p.m.

(788) Pembrolizumab for Patients with Leptomeningeal Metastasis from Solid Tumors: Efficacy, Safety and Cerebrospinal Fluid Biomarkers
Jarushka Naidoo, MBBCH, MHS – Johns Hopkins Sidney Kimmel Cancer Center

12:30–12:50 p.m. EST

12:30–12:50 p.m. EST

Break

12:30–1:30 p.m. EST

Virtual Exhibit and Poster Hall Hours

Concurrent Session 203: Rapid Oral Abstract Presentation: Basic Research
Co-Chairs:
Kristin Anderson, PhD – Fred Huchinson Cancer Research Center
Spencer Wei, PhD – Spotlight Therapeutics
12:50–1:20 p.m. EST

12:50 p.m.

(512) Terminally exhausted CD8+ T cells potentiate the tolerogenic tumor microenvironment as functional
suppressors
Paolo D.A. Vignali, BS — The University of Pittsburgh School of Medicine

12:58 p.m.

(755) CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity (View On-Demand)
Alvaro Teijeira - CIMA Pamplona

1:06 p.m.

(517) Regulatory T cell functional identity is sustained by a glucose: lactate axis that is exploited in the tumor microenvironment
McLane Watson, BS - University Of Pittsburgh

1:14 p.m.

Q&A

Concurrent Session 204: Rapid Oral Abstract Presentation: Clinical
Co-Chairs:
Robyn Gartrell, MD, MS – Columbia University
Saman Maleki, PhD – Western University
12:50–1:20 p.m. EST
(CE Credit Available)

12:50 p.m.

(294) CD8 PET imaging of tumor infiltrating T cells in advanced solid tumors: a phase I first-in-human study of 89Zr-IAB22M2C, a radiolabeled anti-CD8 minibody (View On-Demand)
Michael D. Farwell, MD - University of Pennsylvania

12:58 p.m.

(588) Targeting GITR enhances human tumour-infiltrating T cell functionality in mismatch repair proficient primary colorectal carcinoma and liver metastases (View On-Demand)
Yannick S. Rakké, MD, MSc - Erasmus University Medical Center

1:06 p.m.

(31) Dynamic change of PD-L1 expression on extracellular vesicles predicts response to immune-checkpoint inhibitors in non-small cell lung cancer patients (View On-Demand)
Diego de Miguel Perez, PhD, MSc - University of Maryland

1:14 p.m.

Q&A

Session 205: Toxicities of Cancer Immunotherapy 
Co-Chairs:
Caroline Robert, MD, PhD – Institut Gustave Roussy
Cameron J. Turtle, MBBS, PhD, FRACP – Fred Hutchinson Cancer Research Center
1:20–3:05 p.m. EST
(CE Credit Available)

1:20 p.m.

Toxicities from ICIs (View On-Demand)
Caroline Robert, MD, PhD – Institut Gustave Roussy

1:45 p.m.

Factors Associated with Toxicities of CD19 CAR-T cell Immunotherapy
Cameron J. Turtle, MBBS, PhD, FRACP – Fred Hutchinson Cancer Research Center

2:10 p.m.

CAR-T Studies
Ansuman T. Satpathy, MD, PhD – Stanford

2:35 p.m.

(653) Dasatinib as a rapid pharmacological ON/OFF switch for T cell bispecific antibody-induced T cell activation and cytokine release (View On-Demand)
Gabrielle Leclercq, MSc - Roche

2:50 p.m.

(645) Preclinical development of a novel colon-targeted therapeutic for the treatment of Immune Checkpoint Inhibitor (ICI)-colitis (View On-Demand)
Nazli Dizman, MD - Yale New Haven Hospital

3:05–3:20 p.m. EST

Break

Concurrent Session 206: Vaccines and Immunoprevention
Co-Chairs:
Shizuko Sei, MD – National Cancer Institute
Catherine J. Wu, MD– Dana-Farber Cancer Institute
3:20–4:50 p.m. EST
(CE Credit Available)

3:20 p.m.

Personal Cancer Vaccines: on the Path to Effective Cancer Immunity
Catherine J. Wu, MD – Dana-Farber Cancer Institute

3:50 p.m.

Cancer Vaccines for Lynch Syndrome Carrier
Eduardo Vilar-Sanchez, MD, PhD – The University of Texas MD Anderson Cancer Center

4:20 p.m.

(598) Reversal of epigenetic silencing of cGAS and STING in melanoma enhances the activity of tumor infiltrating lymphocytes (View On-Demand)
Rana Falahat, PhD - Moffit Cancer Center

4:35 p.m.

(612) Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells (View On-Demand)
Kristen Radford, PhD - Mater Research Institute

Concurrent Session 207: Gene Editing
Co-Chairs:
Helen E. Heslop, MD – Baylor College of Medicine
Carl H. June, MD– University of Pennsylvania
3:20–4:50 p.m. EST

3:20 p.m.

Panelists
Matthew Porteus, MD, PhD – Stanford University
Vijay Peddareddigari, MD – Tmunity
Zhaohui Ye, PhD, PI Regulatory – FDA, Center for Biologics Evaluation and Research
Chrystal Louis, MD, MPH – CRISPR Therapeutics

Concurrent Session 208: Bispecific Antibodies in Cancer Immunotherapy
Co-Chairs:
Dimitris Skokos, PhD – Regeneron Pharmaceuticals, Inc.
Mario Sznol, MD– Yale School of Medicine
3:20–4:50 p.m. EST

Human Costimulatory Bispecific Antibodies in Cancer Immunotherapy
Dimitris Skokos, PhD – Regeneron Pharmaceuticals, Inc.

PD1-IL2v: A Next Generation, PD-1-targeted IL-2R Agonist for Cancer Immunotherapy
Pablo Umana – Roche Innovation Center Zurich

(633) Dual-targeting of 4-1BB and OX40 with an ADAPTIR™ bispecific antibody enhances anti-tumor responses to solid tumor
Michelle H. Nelson, PhD - Aptevo Therapeutics

(632) HPN601 is a protease-activated EpCAM-targeting T cell engager with an improved safety profile for the treatment of solid tumors (View On-Demand)
Jack Lin, PhD - Harpoon Therapeutics

(359) AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results (View On-Demand)
Hossein Borghaei, MS, DO - Fox Chase Cancer Center

Concurrent Session 209: Immunometabolism and ICI Resistance
Co-Chairs:
Susan M. Kaech, PhD – Salk Institute
Maxim N. Artyomov, PhD– Washington University School of Medicine in St. Louis
3:20–4:50 p.m. EST
(CE Credit Available)

3:20 p.m.

Metabolic Regulation of Anti-Tumor NK cells
Susan M. Kaech, PhD – Salk Institute

3:45 p.m.

Metabolic Processes that Affect Anti-Tumor Immune Responses (View On-Demand)
Santosh Vardhana, MD, PhD – Memorial Sloan Kettering Cancer Center

4:10 p.m.

Targeting Metabolism to Enhance Cancer Immunotherapy
Jonathan D. Powell, MD, PhD – Johns Hopkins Medicine

4:35 p.m.

(515_ Metabolic reprogramming of antitumor CD8+ T cell immunity
Alison Jaccard, MS – Université de Lausanne

Session 210: E-Poster Viewing Session

4:50–5:20 p.m. EST

5:20–7 p.m. EST

Break

5–6 p.m. EST

Virtual Exhibit and Poster Hall Hours

Replay Session with Live Q&A: Session 202: Late-Breaking Abstracts

7–8 p.m. EST

Co-Chair:
Sandra Demaria, MD – Weill Cornell Medicine

Replay Session with Live Q&A: Session 203: Rapid Oral Abstracts: Basic Research

7–8 p.m. EST

Co-Chairs:
Kristin Anderson, PhD – Fred Hutchinson Cancer Research Center
Spencer Wei, PhD – Spotlight Therapeutics 

Replay Session with Live Q&A: Session 204: Rapid Oral Abstracts: Clinical

7–8 p.m. EST

Co-Chairs:
Robyn Gartrell, MD, MS – Columbia University
Saman Maleki, PhD – Western University

On-Demand Sessions

Update Session: National Cancer Institute (NCI) (View On-Demand)
Norman E. Sharpless, MD - National Cancer Institute

Update Session: Food and Drug Administration (FDA)
Raj Puri, MD, PhD – U.S. Food and Drug Administration

Update Session: FDA Oncology Center of Excellence (FDA OCE)
Marc Theoret, MD – U.S. Food and Drug Administration

Update Session: Cancer Immunotherapy Trials Network (CITN) (View On-Demand)
Martin A. Cheever, MD - Fred Hutchinson Cancer Research Center

Update Session: SITC Policy Committee
George J. Weiner, MD - University of Iowa, Holden Comprehensive Cancer Center

Update Session: SITC Women in Cancer Immunotherapy Network (WIN) (View On-Demand)
Lisa H. Butterfield, PhD – Parker Institute for Cancer Immunotherapy

Update Session: International Neoadjuvant Melanoma Consortium (INMC)
Elizabeth M. Burton, MBA – MD Anderson Cancer Center

SITC Membership Business Meeting
Chair: Mario Sznol, MD – Yale School of Medicine
8-8:30 a.m.

8 a.m.

SITC Membership Business Meeting

Anniversary Awards Ceremony
Chair: Mario Sznol, MD – Yale School of Medicine
8:30–9 a.m. EST

8:30 a.m.

8:32 a.m.

8:37 a.m.

8:47 a.m.

8:51 a.m.

9 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

9:05 a.m.

T cell Therapy of Cancer
Helen E. Heslop, MD – Baylor College of Medicine

9:45 a.m.

Q&A
Helen E. Heslop, MD – Baylor College of Medicine

9:50–10:05 a.m. EST

Break

Session 301: Hot Topic Symposium: COVID-19 and Cancer
Co-Chairs:
Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute, Icahn School of Medicine at Mt. Sinai
10:05 a.m.–12:40 p.m. EST
(CE Credit Available)

10:05 a.m.

Infection/Immunology 
Florian Krammer, PhD - Icahn School of Medicine at Mount Sinai

10:30 a.m.

Infection in Cancer Patients Specifically
Elizabeth V. Robilotti, MD, MPH – Memorial Sloan Kettering Cancer Center

10:55-11:05 a.m.

Break

11:05 a.m.

Repurposing Cancer Immunotherapies for COVID (View On-Demand)
Paolo Ascierto , MD – Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale

11:15 a.m.

Big Data and Informatics – Viral Sequencing and Epitope Identification
Benjamin Greenbaum, MD – Memorial Sloan Kettering Cancer Center

11:25 a.m.

Big data and Informatics – Viral Sequencing and Epitope Identification (View On-Demand)
Marta Luksza, PhD – Icahn School of Medicine at Mount Sinai

11:35 a.m.

Q&A

11:55 a.m.

Panel Discussion: Immunotherapy and COVID Outcomes (ICIs) and Cancer Care in Pandemic
Jia Luo, MD – Memorial Sloan Kettering Cancer Center
Aljosja Rogiers, MD – Institute of Melanoma

12:15 p.m.

(325) Immunotherapy with B cell activating antibody CPI-006 in patients (pts) with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells and memory T effector cells (View On-Demand)
Gerard Criner, MD – Temple University

12:25 p.m.

(475) Incidental finding of colorectal cancer in a COVID-19 patient, followed by deep profiling of SARS-CoV-2-associated immune landscape and tumour microenvironment
Chun Chau Lawrence Cheung, BA, MMedSc - Singapore General Hospital

12:35 p.m.

Closing

12:40–1 p.m. EST

Break

12:30–1:30 p.m. EST

Virtual Exhibit and Poster Hall Hours

1 p.m.

(795) A multicenter phase II trial (SWOG S1609, Cohort 51) of Ipilimumab and Nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) (View On-Demand)
Michael Wagner, MD – University of Washington

1:15 p.m.

(812) Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer (View On-Demand)
Lei Zheng, MD, PhD – Johns Hopkins University School of Medicine

Session 303: Presidential Session
Chair:
Mario Sznol, MD – Yale School of Medicine
1:30–2:55 p.m. EST
(CE Credit Available)

1:30 p.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

1:35 p.m.

(528) Sexual dimorphism in myeloid-derived suppressor cells promote GBM progression in females via IL-1b (View On-Demand)
Defne Bayik, PhD - Cleveland Clinic

1:50 p.m.

(36) Molecular events regulating solid tumor cell responses to natural killer cells (View On-Demand)
Michal Sheffer, PhD - Dana-Farber Cancer Institute

2:05 p.m.

Expert Discussant
Jeffrey Miller, MD – University of Minnesota

2:15 p.m.

(629) Targeting a shared TP53 neoantigen with bispecific T cell retargeting antibody
Emily Hsiue, MD - Oncology

2:30 p.m.

(465) Radiotherapy and CTLA-4 blockade expand anti-tumor T cells differentiation states and cooperate with CD40 agonist to induce tumor rejection (View On-Demand)
Nils Rudqvist, PhD - The University of Texas MD Anderson Cancer Center

2:45 p.m.

Expert Discussant
Robert H. Vonderheide, MD, Dphil – University of Pennsylvania Perelman School of Medicine

2:55–3:10 p.m. EST

Break

Concurrent Session 304: Novel immunotherapies in Myeloid Malignancies
Co-Chairs:
Naval Daver, MD – The University of Texas MD Anderson Cancer Center
Marcela V. Maus, MD, PhD– Massachusetts General Hosptial
3:10–4:40 p.m. EST
(CE Credit Available)

3:10 p.m.

CD47 Macrophage Checkpoint-Based Immunotherapy (Lymphomas, MDS, AML) (View On-Demand)
David Sallman, MD – Moffitt Cancer Center

3:30 p.m.

Bispecific Antibodies
Marion Subklewe, MD – University of Munich

3:50 p.m.

CAR T for AML (View On-Demand)
Elizabeth Budde, MD, PhD – City of Hope

4:10 p.m.

Emerging and personalized cellular therapy approaches for myeloid diseases (View On-Demand)
Marco L. Davila, MD, PhD – Moffitt Cancer Center

Concurrent Session 305: Reverse Translation for Clinical Trials
Co-Chairs:
Matthew Galsky, MD – Tisch Cancer Institute at Mount Sinai Medical Center
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center
3:10–4:40 p.m. EST
(CE Credit Available)

3:10 p.m.

Rational Design of Tumor-Specific Therapeutic and Biomarker Strategies through Reverse Translational Studies (View On-Demand)
Sangeeta Goswami, MD, PhD – MD Anderson Cancer Center

3:30 p.m.

Clinical Trial Design Considerations to Facilitate Reverse Translation
Thomas Marron, MD, PhD – Icahn School of Medicine at Mount Sinai

3:50 p.m.

Identifying Novel Therapeutics Targets to Overcome Immune Checkpoint Blockade Resistance Through Reverse Translation
Sanjeev Mariathasan, PhD – Genentech
(*No Credit)

4:10 p.m.

(332) Novel TGF-β signatures in metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab
Keun-Wook Lee, MD, PhD – Seoul National University College of Medicine

4:25 p.m.

(352) Updated clinical data from the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab (View On-Demand)
Ezra Cohen, MD – University of California San Diego

Concurrent Session 306: Engineering Immunity: Biomolecular and Genetic Approaches to Generating Novel Therapeutic Function
Co-Chairs:
Yvonne Chen, PhD – University of California, Los Angeles
Kole T. Roybal, PhD – University of California, San Francisco
3:10–4:40 p.m. EST
(CE Credit Available)

3:10 p.m.

Biomaterials – Basic Biology (View On-Demand)
Jennifer H. Elisseeff, PhD – Johns Hopkins School of Medicine

3:35 p.m.

Biomaterials – Immunotherapy
Darrell J. Irvine, PhD – MIT

4 p.m.

Lymphatic Transport and Anti-Tumor Immunity
Amanda Lund, PhD – NYU Grossman School of Medicine

4:25 p.m.

(587) Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models (View On-Demand)
Kurt Jenkins, PhD – Xilio Therapeutics
(*No Credit)

Concurrent Session 307: B Cells
Co-Chairs:
Tullia Bruno, PhD – UPMC Hillman Cancer Center
Wolf Fridman, MD, PhD – Cordeliers Research Centre
3:10–4:40 p.m. EST
(CE Credit Available) 

3:10 p.m.

B cells and Tertiary Lymphoid Structures as biomarkers for prognosis and immunotherapy (View On-Demand)
Wolf H. Fridman, MD, PhD – Cordeliers Research Centre

3:30 p.m.

The Role of B cells and TLS in Immunotherapy Response
Jennifer Wargo, MD – The University of Texas MD Anderson Cancer Center

3:50 p.m.

Targeting tertiary lymphoid structure heterogeneity and B cell function in non-small cell lung cancer patients
Tullia C. Bruno, PhD – UPMC Hillman Cancer Center

4:10 p.m.

(536) Divergent cancer etiologies drive distinct B cell signatures and tertiary lymphoid structures in head and neck cancer
Ayana Ruffin, MS – University of Pittsburgh

4:17 p.m.

(167) B-cell-based vaccination elicit potent immunity against glioblastoma (View On-Demand)
Catalina Lee-Chang, PhD – Northwestern University

4:24 p.m.

Expert Discussant
Brad Nelson, PhD – Deely Research Centre at BC Cancer Agency

4:30 p.m.

Q&A

Session 308: E-Poster Viewing Session

4:40–5:10 p.m. EST

4:30–5:30 p.m. EST

Virtual Exhibit and Poster Hall Hours

5:10–7 p.m. EST

Break

Replay Session with Live Q&A: Session 302: Late-Breaking Abstracts

7–8 p.m. EST

Chair:
Roberta Zappasodi, PhD – Weill Cornell Medicine

On-Demand Sessions

Update Session: National Cancer Institute (NCI) (View On-Demand)
Norman E. Sharpless, MD - National Cancer Institute

Update Session: Food and Drug Administration (FDA)
Raj Puri, MD, PhD – U.S. Food and Drug Administration

Update Session: FDA Oncology Center of Excellence (FDA OCE)
Marc Theoret, MD – U.S. Food and Drug Administration

Update Session: Cancer Immunotherapy Trials Network (CITN) (View On-Demand)
Martin A. Cheever, MD - Fred Hutchinson Cancer Research Center

Update Session: SITC Policy Committee
George J. Weiner, MD - University of Iowa, Holden Comprehensive Cancer Center

Update Session: SITC Women in Cancer Immunotherapy Network (WIN) (View On-Demand)
Lisa H. Butterfield, PhD – Parker Institute for Cancer Immunotherapy

Update Session: International Neoadjuvant Melanoma Consortium (INMC)
Elizabeth M. Burton, MBA – MD Anderson Cancer Center

8:30 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

8:33 a.m.

Team Science Award

Co-Chairs:
James P. Allison, PhD – The University of Texas MD Anderson Cancer Center
John Wherry, PhD – University of Pennsylvania
9–10:30 a.m. EST
(CE Credit Available)

9 a.m.

New insights into mechanisms of CTLA-4 and PD-1 blockade in cancer therapy (View On-Demand)
James P. Allison, PhD – The University of Texas MD Anderson Cancer Center

9:15 a.m.

Epigenetics of CD8 T Cell Exhaustion
John Wherry, PhD – University of Pennsylvania

9:30 a.m. 

Re-assessing the mechanism of checkpoint inhibition
Ira Mellman, PhD – Genentech
(*No Credit)

10:30 a.m.

Understanding immune responses to cancer using single-cell data
Matthew Spitzer, PhD – University of California San Francisco
(*No Credit)

10:30–10:45 a.m. EST

Break

10:45 a.m.

Introduction
Nir Hacohen, PhD – Broad Institute

10:55 a.m.

Spatial Analysis of Immune Responses in Tumors
Leeat Keren, PhD – Stanford University

11:20 a.m.

Blood-Based Predictors of Tumor Immunity (View On-Demand)
Jane Grogan, PhD – ArsenalBio
(*No Credit)

11:45 a.m.

Capturing heterogeneity and the HLA-presented landscape in melanoma (View On-Demand)
Yardena Samuels, PhD – Weizmann Institute of Science

12:10 p.m.

(62) Identify immune cell types and biomarkers associated with immune-related adverse events using single cell RNA sequencing
Jiamin Chen, PhD – Stanford University Medical School

12:25 p.m.

(21) Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients 
Michal Harel, PhD – Oncohost LTD
(*No Credit)

12:40–1 p.m. EST

Break

Session 402: E-Poster Viewing Session

1–1:30 p.m. EST

Session 403: Poster Symposium
Co-Chairs:
Niroshana Anandasabapathy, MD, PhD – Weill Cornell Medicine
Sangeeta Goswami, MD, PhD – The University of Texas MD Anderson Cancer Center
1:30–2:45 p.m. EST

1:30 p.m.

(545) Tumor-specific cytolitic CD4 T cells mediate protective immunity against human cancer (View On-Demand)
Camilla Jandus, MD, PhD – University of Geneva

 1:40 p.m.

(206) An immune-competent tumor organoid platform to test novel immune checkpoint combinations targeting the receptor CD47 in triple negative breast cancer
Elizabeth R. Stirling, MS – Wake Forest University

 1:50 p.m.

(549) Characterizing Double Positive T cells in the Tumor Microenvironment: a tale of promiscuous cell fates (View On-Demand)
Sara Schad, BS – Memorial Sloan Kettering Cancer Center

 2 p.m.

(152) Adoptive T cell therapy targeting somatic p53 mutations (View On-Demand)
Peter Kim, PhD – National Institute of Health

 2:10 p.m.

(744) Single cell profiling of acute myeloid leukemia (AML) and its microenvironment reveals a CD8 continuum and adaptable T cell plasticity in response to PD-1 blockade-based therapy (View On-Demand)
Hussein Abbas, MD, PhD – The University of Texas MD Anderson Cancer Center

2:20 p.m.

(248) Immunotherapy persister cells uncovered by dynamic single-cell RNA-sequencing (View On-Demand)
Kartik Sehgal, MD – Dana Farber Cancer Institute

2:30 p.m.

Q&A

2:45–3 p.m. EST

Break

Session 404: Next Generation Immunotherapy Combinations: Navigating FDA, Clinical Trial Design, Diagnostics and Novel Biomarkers
Co-Chairs:
Emily Hopewell, PhD – Indiana University
Ke Liu, MD, PhD – Food and Drug Administration (FDA)
Jason Luke, MD – UPMC Hillman Cancer Center
Marc Theoret, MD – Food and Drug Administration (FDA), CDER
3–4:30 p.m. EST
(CE Credit Available)

3 p.m.

Welcome
Jason Luke, MD – UPMC Hillman Cancer Center

3:05 p.m.

Navigating the Road to Developing and Pursuing Novel Cellular and Non-Cellular Combination Immunotherapy Clinical Trials: FDA Overview (View On-Demand)
Adnan A. Jaigirdar, MD, FACS - Food and Drug Administration

3:20 p.m.

FDA Perspective on Areas of Research Needed in Advancing Neo-Adjuvant Immunotherapy Toward Clinical Practice (View On-Demand)
Nicole Drezner, MD – Food and Drug Administration

3:35 p.m.

Difficulties and opportunities in developing cellular therapy and cancer therapeutics clinical trials: science and logistics for investigators (View On-Demand)
Cassian Yee, MD – The University of Texas MD Anderson Cancer Center

3:50 p.m.

Improving patient selection in cellular therapy studies and neoadjuvant trials (View On-Demand)
Rodabe N. Amaria, MD – The University of Texas MD Anderson Cancer Center

4:05 p.m.

Panel Discussion

4:30 p.m.

SITC 2020 Closing Remarks
Mario Sznol, MD – Yale School of Medicine

On-Demand Sessions

Update Session: National Cancer Institute (NCI) (View On-Demand)
Norman E. Sharpless, MD - National Cancer Institute

Update Session: Food and Drug Administration (FDA)
Raj Puri, MD, PhD – U.S. Food and Drug Administration

Update Session: FDA Oncology Center of Excellence (FDA OCE)
Marc Theoret, MD – U.S. Food and Drug Administration

Update Session: Cancer Immunotherapy Trials Network (CITN) (View On-Demand)
Martin A. Cheever, MD - Fred Hutchinson Cancer Research Center

Update Session: SITC Policy Committee
George J. Weiner, MD - University of Iowa, Holden Comprehensive Cancer Center

Update Session: SITC Women in Cancer Immunotherapy Network (WIN) (View On-Demand)
Lisa H. Butterfield, PhD – Parker Institute for Cancer Immunotherapy

Update Session: International Neoadjuvant Melanoma Consortium (INMC)
Elizabeth M. Burton, MBA – MD Anderson Cancer Center